P-003. Paritaprevir+Ritonavir+Ombitasvir+Dasabuvir±Ribavirin treatment in HCV infected chronic hemodialysis patients: A single center experience

INTRODUCTION: The prevelance of HCV in Turkey is 0.5–1.0%. According to Turkish Society of Nephrology registry, anti-HCV positivity rate was 6.94% in chronic hemodialysis patients in 2013. Beyond the liver-related mortality, HCV infection increases all kind of mortality in hemodialysis patients. In...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Turk J Gastroenterol
Autores principales: Danis, Nilay, Pullukcu, Husnu, Yamazhan, Tansu, Ersoz, Galip, Unal, Nalan Gülsen, Gunsar, Fulya, Turan, Ilker, Karasu, Zeki, Akarca, Ulus Salih
Formato: Artigo
Lenguaje:Inglês
Publicado: Turkish Society of Gastroenterology 2019
Materias:
AASLD - TASL CONNECT REGIONAL MEETING, March 15–16, 2019 - İstanbul, Turkey
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7021023/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/tjg.2019.09
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares